B · Normal
[Boji Pharmaceuticals: There are currently multiple projects to be transferred, which will bring positive contributions to performance in the future] On October 28, Boji Pharmaceuticals stated at an investor telephone conference on the 27th that in the first three quarters of 2026, the company's independent research and development and technological achievement transformation service revenue was 11.5 million yuan, and it is expected to continue to generate related income in the future, and the gross profit margin of this business is relatively high. Currently, the company has multiple projects to be transferred, which will make a positive contribution to the company's performance in the future.
Comments